Viral glycoprotein (GP)

Viral glycoproteins are specialized proteins embedded in the lipid envelope of many viruses, playing a critical role in the viral life cycle. They primarily mediate the initial stages of infection, including host cell recognition, attachment to specific cellular receptors, and the subsequent fusion of viral and host membranes [1, 2]. Because they are exposed on the surface of the virion, they are the primary targets for the host's humoral immune response and are central to vaccine development [3]. In clinical practice, these proteins are targeted by various antiviral therapies, such as fusion inhibitors and monoclonal antibodies, which aim to block viral entry [4, 5]. However, the high mutation rate of many viral glycoproteins poses a significant challenge, often leading to the emergence of resistant strains and necessitating the development of broad-spectrum or updated therapeutic agents [6]. This entry is classified as incorrect/broad because 'Viral glycoprotein' refers to a general class of proteins across diverse viral families rather than a specific molecular target.

Other names

Viral envelope proteinViral surface proteinSpike proteinEnv proteinViral attachment protein

Drugs targeting viral glycoproteins typically act as entry inhibitors by blocking the binding of the glycoprotein to host cell receptors or by preventing the conformational changes required for the fusion of viral and host membranes [1, 4].